ClinicalTrials.gov
public full text
Public Domain
Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity
Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines. It has been suggested that sodium-glucose transporter-2 (SGLT2) inhibitors may reduce the damage to the heart caused by anthracycline chemotherapy. The investigators wish to determine whether dapagliflozin (SGLT2 inhibitor) taken daily during chemotherapy will reduce the rate of cardiotoxicity.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Caloric Restriction and Exercise for Protection From Anthracycline Toxic Effects#1008388
- Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients#1073006
- Detection of Chemotherapy Induced Cardiotoxicity#833108
- Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses#805592
- Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol#913217
Record · ID 1030904
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive